PRODUCT INFORMATION

SARS-CoV-2 Spike Glycoprotein Neutralizing Monoclonal Antibody (Clone 57)

Item No. 32501

Overview and Properties

Contents: This vial contains 100 µg of protein A-affinity purified monoclonal antibody.
Synonyms: SARS-CoV-2 Spike RBD, SARS-CoV-2 Spike Receptor Binding Domain, SARS-CoV-2 Surface Glycoprotein RBD, SARS-CoV-2 Surface Glycoprotein Receptor Binding Domain, Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein Receptor Binding Domain, Severe Acute Respiratory Syndrome Coronavirus 2 Surface Glycoprotein Receptor Binding Domain
Immunogen: Recombinant SARS-CoV-2 spike RBD (C-terminal mouse IgG1 Fc-tagged)
Cross Reactivity: See page 2
Species Reactivity: See page 2
Form: Liquid
Storage: -80°C (as supplied)
Stability: ≥1 year
Storage Buffer: 0.2 µm filtered solution in PBS
Clone: 57
Host: Mouse
Isotype: IgG2b
Applications: ELISA, Flow cytometry (FC), Immunocytochemistry (ICC), and Immunofluorescence (IF); the recommended starting concentration is 0.5-1 µg/ml for ELISA, 10-40 µg/ml for FC, and 10-50 µg/ml for ICC and IF. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

Images



Immunofluorescent labeling of SARS-CoV-2 spike glycoprotein-overexpressing HEK293 cells labeled with SARS-CoV-2 Spike Glycoprotein Neutralizing Monoclonal Antibody (Clone 57) followed by a Alexa Fluor® 488-conjugated secondary antibody.



Flow cytometric analysis of SARS-COV-2 spike glycoprotein-overexpressing HEK293 cells. Cells were labeled with purified SARS-CoV-2 Spike Glycoprotein Neutralizing Monoclonal Antibody (Clone 57) followed by a FITC-conjugated secondary antibody. The fluorescence histogram was derived from gated events with the forward and side light-scatter characteristics of intact cells.

Conc. (µg/mL)	Inhibition%
100	95.51%
10	93.32%
1	75.69%
0.1	10.11%

The neutralization activity is measured by microneutralization (MN) assay *in vitro*. The virus MN test was performed on 293T-ACE2 cells infected with SARS-CoV-2 spike glycoprotein pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of SARS-CoV-2 Spike Glycoprotein Neutralizing Monoclonal Antibody (Clone 57). Rate of inhibition was determined by comparing the relative light unit (RLU) of luciferase reporter in different antibody concentrations. The IC_{50} value is typically 0.41 µg/ml for the wild-type protein.

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION

Reactivity

Cross Reactivity: (+) SARS-CoV-2 Omicron (BA.1.1) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1+S2,
SARS-CoV-2 spike glycoprotein S1 subunit

(-) SARS-CoV-2 Omicron (B.1.1.529) S1+S2 trimer,
SARS-CoV-2 Omicron (B.1.1.529) spike glycoprotein S1 subunit,
SARS-CoV-2 Omicron (BA.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.2) spike glycoprotein S1 subunit,
SARS-CoV-2 Omicron (BA.2) spike glycoprotein S1 subunit NTD,
SARS-CoV-2 (BA.2.75) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.2.75.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 (BA.4.6) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BF.7) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BQ.1.1) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 XD (BA.1 x AY.4) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1 subunit NTD,
SARS-CoV spike glycoprotein S1 subunit (mouse Fc-tagged),
SARS-CoV spike glycoprotein RBD (His-tagged),
MERS-CoV spike glycoprotein S1 subunit,
HCoV-HKU1 (isolate N1) spike glycoprotein S1 subunit,
HCoV-HKU1 (isolate N5) spike glycoprotein S1 subunit,
HCoV-NL63 spike glycoprotein S1 subunit,
HCoV-229E spike glycoprotein S1 subunit,
HCoV-OC43 spike glycoprotein S1+S2 ECD

Species Reactivity: (+) SARS-CoV-2,
SARS-CoV-2 Delta (B.1.617.2),
SARS-CoV-2 Omicron (BA.1.1)

(-) SARS-CoV-2 Omicron (BA.2),
SARS-CoV-2 Omicron (BA.2.12.1),
SARS-CoV-2 (BA.2.3.20),
SARS-CoV-2 (BA.2.75),
SARS-CoV-2 Omicron (BA.2.75.2),
SARS-CoV-2 Omicron (BA.4),
SARS-CoV-2 Omicron (BA.4.6/BF.7),
SARS-CoV-2 Omicron (BA.5),
SARS-CoV-2 Omicron (BQ.1.1),
SARS-CoV-2 Omicron (XBB)

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION

Description

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive-stranded RNA virus, a member of the *Betacoronavirus* genus, and the causative agent of COVID-19.[1-5] The SARS-CoV-2 spike glycoprotein, also known as the surface glycoprotein, is located on the outer envelope of the virion.[1] It is composed of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.[6,7] The S1 subunit contains the receptor-binding domain (RBD), which binds to the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), and the S1 and S2 subunits are cleaved by the protease TMPRSS2 to facilitate viral fusion with the host cell membrane.[8-10] In this way, ACE2 acts as the functional receptor for SARS-CoV-2. SARS-CoV-2 infection can result in the production of neutralizing antibodies, which bind to the SARS-CoV-2 spike RBD preventing further viral entry and infection, starting approximately 4-10 days after symptom onset.[11,12] Cayman's SARS-CoV-2 Spike Glycoprotein Neutralizing Monoclonal Antibody (Clone 57) disrupts the spike glycoprotein RBD-ACE2 interaction and can be used for ELISA, flow cytometry (FC), immunocytochemistry (ICC), and immunofluorescence (IF) applications.

References

1. Kandeel, M., Ibrahim, A., Fayez, M., *et al.* From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* **92(6)**, 660-666 (2020).
2. Lu, R., Zhao, X., Li, J., *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **395(10224)**, 565-574 (2020).
3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* **24(4)**, 2012-2019 (2020).
4. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., *et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb. Res.* **191**, 145-147 (2020).
5. Yang, F., Shi, S., Zhu, J., *et al.* Analysis of 92 deceased patients with COVID-19. *J. Med. Virol.* **92(11)**, 2511-2515 (2020).
6. Liu, Z., Xiao, X., Wei, X., *et al.* Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med. Virol.* **92(6)**, 595-601 (2020).
7. Walls, A.C., Park, Y.-J., Tortorici, M.A., *et al.* Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181(2)**, 281-292 (2020).
8. Hoffmann, M., Kleine-Weber, H., Schroeder, S., *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181(2)**, 271-280 (2020).
9. Yan, R., Zhang, Y., Li, Y., *et al.* Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* **267(6485)**, 1444-1448 (2020).
10. Wrapp, D., Wang, N., Corbett, K.S., *et al.* Cryo-EM structure of the 2019-nCov spike in the prefusion conformation. *Science* **367(6483)**, 1260-1263 (2020).
11. Wang, A., Zhang, L., Sang, L., *et al.* Kinetics of viral load and antibody response in relation to COVID-19 severity. *J. Clin. Invest.* **130(10)**, 5235-5244 (2020).
12. Xiang, F., Wang, X., He, X., *et al.* Antibody detection and dynamic characteristics in patients with coronavirus disease 2019. *Clin. Infect. Dis.* **71(8)**, 1930-1934 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM